biopharm, who could help?
Well I know you are thinking about some players:
1) CALICO (your favourite :). If you are in the business of stopping ageing then you need to be sure people don't die before that from something else. Would CALICO think it to be THEIR role and be interested in Bavituximab for that reason? Probably not.
2) B&MGates. OK, viral is their terrain. But if you have a vaccine combined with Bavituximab and an immune response then you can stop malaria but you'll have even lesser candidate pharma's wanting to devellop drugs for it as the market will eliminate itself.
3) The many foundations. Yeh, but they are relatively poor compared to BP and spread all over the place. They might contribute if Bavi brings something to the table for what they do but it will be a drop on a boiling plate.
4) Pseudo Healthcare departments. Google, Microsoft, IBM, etc they all have them. It is not their core business and they all are on the topic because they think it can sooner or later bring something to their core business. Watson API are for free and we lowered the price to 0.0025$ per query and still you will see that the business model behind it is NOT AT ALL BIOTECHNOLOGY or even PHARMA oriented. It's Artificial Intelligence with leeman access in direct competition with the kind like Wolfram and lately Google that has throw its complete set of AI tools in the open community.
5) BP? Yes, but only as cheap as possible and possibly to deploy it in such a limited way that it INCREASES RES PONDERS but does NOT manifest auto-immune responses. And for that someone will have to go over CEO King's death body. Those that spoke with him might have heard him say that he is really going for bavituximab usage at max. There are SOME BP's that are however open for the idea. GILD is one of them. They have experience with marketing a drug of which the customers do not endlessly stay on it. So Bavi would be a good replacement that due to its wide range of application could for a LONG time provide income. And then they'll find something else next and so on. JNJ/Jan might be convinced as they missed the boat IMO in IO oncology and with Bavi they could get their share of the pie.
6) Financial companies? There are of sure some that want investments in Bavituximab but NOT in this stage. Although they have experts in all areas and therefor ALSO in biotech, they do NOT go as deep as the Scientists at BP and they will be afraid to miss something as long as there is no approval. So they will rather hold PPHM shares from the open market and not do a full acquisition.
7) Philips, Siemens, Agfa and other medical equipment vendors might have an interest in PNG applications for digital imaging but that is probably more suited for leverage buy out then for total acquisition.
So you see, IMO, it will have to come from category 5 or it will be a going it alone scenario (which we all want to avoid). Except for the two mentioned Pfizer has the pocket depth and AstraZeneca, BMY are to small to make meaningful SINGLE STRIKE offers. Roche, Novartis, Merck etc can make step offers as Roche did with Genentech.
So IMO in stead of counting on that type of help I'dd say PPHM must start closing a minefield of many small partnerships with upfront payments, mile-stones, reverse mile-stones and licensing/profit participation based on the fact that MANY will need bavituximab to win the IO Combinations war. Then we have what we want (partnerships), all BPs would have an interest in Bavi advancement, the FDA would see a kind of monopoly/bottleneck on PS targeting, BPs have the means to advance Bavi for combination in the condition they want to compete in with their drug and PPHM get income and PPS benefits. Everybody happy.
Market Data 
Markets 
AI
